Johnson & Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter ...

Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated ...

(Reuters) - Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects ...

They began 2024 saying "I do" to each other at a ritzy wedding ceremony. Back then, a glamorous Scottsdale couple hardly ...

Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics ...

For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.

Key Takeaways Johnson & Johnson's fourth quarter sales met estimates, while net income fell short.After adjusting for ...

Adding a monoclonal antibody cocktail to the standard treatment for inoperable liver cancer nearly doubled the amount of time ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Johnson & Johnson reported better-than-expected quarterly revenue and profit on higher sales of cancer drugs and some medical devices. But shares slipped 3.2% to $143.35 in Wednesday morning trading, ...

Corcept Therapeutics' long-term goal is $3 billion revenue by 2029, driven by the new drug Relacorilant. Click here to read ...